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Background/aim: To investigate if there is any association between the serum folate and vitamin B12 status and the depressive symptoms
in postmenopausal women.
Materials and methods: The study included 95 postmenopausal women. The Center for Epidemiologic Studies Depression Scale
(CES-D) was used to assess their depressive symptoms. The investigated women were classified into 2 groups based on the existence of
depressive symptoms. These 2 groups were compared in terms of folic acid and vitamin B12 levels.
Results: Among 95 cases, 27 postmenopausal women scored 16 or more on the CES-D scale and were classified as the depressive group
(Group 1), and 68 postmenopausal women scored 15 or less and were classified as the nondepressive group (Group 2). The serum levels
of folate were 11.5 ± 5.4 ng/mL in group 1 and 12.3 ± 5.3 ng/mL in group 2. The concentrations of vitamin B12 were 456.2 ± 343.4 pg/
mL in group 1 and 446.5 ± 165.1 pg/mL in group 2. The folate and vitamin B12 levels did not significantly correlate to the frequency of
depressive symptoms (P = 0.52 and P = 0.24, respectively).
Conclusion: In this study, no correlation was detected between serum folate and vitamin B12 levels and depressive symptoms in
postmenopausal women. Supplementation of folic acid and vitamin B12 for postmenopausal women does not seem to be an effective
intervention to reduce depressive symptoms.
Key words: Depressive symptoms, folate, menopause, vitamin B12

1. Introduction
Menopause is a physiologic period during which estrogen
production in the ovaries ends and many climacteric
symptoms, including depression, may arise (1). Depression
may be debilitating, and many patients may not respond
to antidepressant treatment or may discontinue drug
therapy due to side effects. An improved response to
antidepressants is reported in women when administered
in combination with folic acid supplements; thus, folate
status might be related to depression (2). It has been
reported that disturbances in folate-dependent one-carbon
metabolism may contribute to neurodegenerative diseases,
including depression (3). Slapien et al. suggested that folate
and possible methionine metabolism involvement may
play a significant role in the development of depression in
postmenopausal women (4). Folate, a naturally occurring B
vitamin, is necessary for the synthesis of the trimonoamine
* Correspondence: ozlem.sengul@yahoo.com

neurotransmitters implicated in depression and may
enhance the effects of a traditional antidepressant (5). The
active metabolite of folate is required for the remethylation
of homocysteine in the production of methionine,
which is involved in a number of biochemical processes
involving the monoamine neurotransmitters serotonin,
norepinephrine, and dopamine (6). Thus, a deficiency in
folate may disturb the production and function of these
neurotransmitters. A deficiency of either folate or vitamin
B12 causes elevated homocysteine concentrations, which
may contribute to the pathogenesis of a major depressive
disorder (7). The Rotterdam study of older men and
women found that hyperhomocysteinemia, vitamin B12
deficiency, and folate deficiency were related to depressive
disorders (8). Nanri also suggested an inverse relationship
between serum folate and 25-hydroxyvitamin D levels and
depressive symptoms (9).
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In light of these findings, supplementation of vitamins
may offer hope as a safe and effective intervention to
reduce the burden of depression. Since depression is
frequently observed in the postmenopausal period and
significantly deteriorates life quality, it is important to
overcome depression during this period. There are studies
in the literature evaluating the relationships among folate,
vitamin B12, and depressive symptoms; in this study, we
especially aim to clarify the association between the serum
folate and vitamin B12 status and the depressive symptoms
in the postmenopausal period and to make a consideration
about supplementation of folic acid and vitamin B12.
2. Materials and methods
The study included 95 postmenopausal women. It was
carried out in the Yenimahalle State Hospital between
August 2010 and February 2011. All women were at
least 1 year postmenopausal. Patients on a fortified diet
containing folate or vitamin B12 and taking folate or
vitamin B12 supplements; with malabsorption disorders;
who had a history of psychological care or treatment; or
who were receiving hormone replacement therapy were
excluded from the study. Informed consent was received
from all patients enrolled in the study. The Turkish version
of the Center for Epidemiologic Studies Depression Scale
(CES-D) (10) was used to assess the women’s depressive
symptoms (Table 1). It is a self-report scale used to measure
the severity of depressive symptoms. Participants scored
the frequency of depressive symptoms in the week prior to
assessment. Total CES-D scores range from 0 to 60. A total
score of 16 or higher was considered depression. Serum
folate and vitamin B12 concentrations were measured in
all cases. Vitamin B12 (reference range: 211–911 pg/mL)
and folate (reference range: 5.38–24 ng/mL) levels were
measured by autoanalyzer. The investigated women were
classified in 2 groups based on the existence of depressive
symptoms according to the CES-D scale. These 2 groups
were compared in terms of folic acid and vitamin B12
status.
The normal distribution of the quantitative data
was evaluated by the Shapiro–Wilks test. In normally
distributed data, the variability between the 2 groups
was evaluated by independent samples t-test. In the
data that were not normally distributed, the variability
of the 2 groups was evaluated by the Mann–Whitney U
test. Numerical data were presented as mean ± standard
deviation. A P-value of ≤ 0.05 was accepted as statistically
significant. Data analysis was performed using SPSS 16.0.
3. Results
Among 95 cases, 27 postmenopausal women scored
16 or higher on the CES-D scale and were considered
as the depressive group (Group 1). The remaining 68
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postmenopausal women scored 15 or lower and were
considered as the nondepressive group (Group 2).
The average age of patients (range: 41–73 years)
was 50.5 ± 5.3 years in group 1 and 52.3 ± 7.0 years in
group 2 (P = 0.23). There were no statistically significant
differences between the 2 groups in terms of age, smoking,
and duration of menopause (Table 2).
There were 3 surgical and 24 natural menopause cases
in group 1 and 9 surgical and 59 natural menopause cases in
group 2. There was no statistically significant relationship
between menopause type and depression (P = 0.54).
The serum levels of folate were 11.5 ± 5.4 ng/
mL in group 1 and 12.3 ± 5.3 ng/mL in group 2. The
concentrations of vitamin B12 were 456.2 ± 343.4 pg/mL
in group 1 and 446.5 ± 165.1 pg/mL in group 2. There were
no folate- or vitamin B12-deficient patients in group 1. In
group 2, 1 patient had folate deficiency and 2 patients had
vitamin B12 deficiency. Serum levels of folate and vitamin
B12 were not significantly different between depressive
and nondepressive postmenopausal women (P = 0.52 and
P = 0.24, respectively).
There were 9 smokers (who smoke every day,
independent of the number of cigarettes per day) and 18
nonsmokers in group 1 and 13 smokers and 55 nonsmokers
in group 2. There was no statistically significant relationship
between smoking and depression (P = 0.11).
There was also no statistically significant relationship
between duration of menopause period and levels of folate
and vitamin B12 (P = 0.20 and P = 0.24, respectively).
However, a statistically significant relationship was found
between folate and vitamin B12 levels (P = 0.017).
4. Discussion
The transition to menopause and its changing hormonal
milieu are associated with an increased risk of depressed
mood, not only for those with a history of depression but
also for women with no history of depression, supporting
the hypothesis that menopausal transition is a period of
vulnerability framed by the changing hormonal status
of ovarian aging (11). Bromberger et al. suggested that
the risk for depressive symptoms increased with the
menopausal transition, stayed elevated through early
postmenopause, and was independent of relevant
demographic, psychosocial, behavioral, and health factors
(12). Conversely, there was no significant relationship
between duration of menopausal period and depressive
symptoms in our study.
It has been suggested that folate and vitamin B12 have a
role in depression, but the results of epidemiologic studies
on this issue have been inconsistent. It is hypothesized that
the deficiencies in folate and vitamin B12 can lead to elevated
homocysteine concentrations, which have been associated
with depression (13–17). The consumption of certain
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Table 1. The Center for Epidemiologic Studies Depression Scale (CES-D) (10).
Center for Epidemiologic Studies Depression Scale (CES-D), NIMH
Below is a list of the ways you might have felt or behaved. Mark how often you have felt this way during the past week.
During the Past Week
Rarely or none
of the time
(less than 1 day)

Some or a
little of the time
(1–2 days)

Occasionally or a
moderate amount of
time (3–4 days)

Most or all
of the time
(5–7 days)









































6. I felt depressed.









7. I felt that everything I did was an effort.









8. I felt hopeful about the future.









9. I thought my life had been a failure.









10. I felt fearful.









11. My sleep was restless.









12. I was happy.









13. I talked less than usual.









14. I felt lonely.









15. People were unfriendly.









16. I enjoyed life.









17. I had crying spells.









18. I felt sad.









19. I felt that people dislike me.









20. I could not get “going.”









1. I was bothered by things that usually
don’t bother me.
2. I did not feel like eating; my appetite
was poor.
3. I felt that I could not shake off the
blues even with help from my family or
friends.
4. I felt I was just as good as other
people.
5. I had trouble keeping my mind on
what I was doing.

SCORING: Zero for answers in the first column, 1 for answers in the second column, 2 for answers in the third column, 3 for answers in
the fourth column. The scoring of positive items is reversed. Possible range of scores is 0 to 60, with higher scores indicating the presence
of more symptomatology.
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Table 2. The characteristics and findings of patients included in the study.
Group 1

Group 2

P-value

Age (years)

50.5 ± 5.3

52.3 ± 7.0

0.23

Duration of menopause period (years)

3.6 ± 3.7

5.1 ± 6.0

0.36

Smokers/nonsmokers

9/18 (33.3%)

13/55 (19.1%)

0.11

Folate (ng/mL)

11.5 ± 5.4

2.3 ± 5.3

0.52

Vitamin B12 (pg/mL)

465.2 ± 343.4

446.5 ± 165.1

0.24

The variability between the 2 groups was evaluated by independent samples t-test.

vitamin B complexes, through diet or supplementation,
decreases the total plasma concentration of homocysteine
and may enhance responses to standard antidepressant
treatment. Treatment with vitamin B complexes can reduce
the long-term prevalence of depression in at-risk people,
such as stroke survivors (18). Brocardo et al. suggested
that folate has a synergistic antidepressant-like effect with
fluoxetine, probably via serotonergic and noradrenergic
systems (19). Folic acid is a promising nutrient in the
augmentation of depression treatment efficiency, but there
are not enough data for prescription of folic acid as an
aid in patients with depression. Lazarou et al. suggested
that folic acid levels should be examined in individuals at
increased risk for folic acid deficiency, as well as in patients
who do not respond to pharmaceutical treatment (20).
On the other hand, Nanri et al. suggested that while
higher serum folate was associated with decreased
prevalence of depressive symptoms in men, such a
relationship was not observed in women (21). Walker et
al. reported that neither folic acid plus vitamin B12 nor
physical activity were effective in reducing depressive
symptoms (22). Watanabe et al. found no significant
associations between the incidence of depression and
serum folate and homocysteine levels in the first trimester
of pregnancy and reported that folate and homocysteine
concentrations and folate consumption may not be
protective against depression in early pregnancy (23).
Miyake et al. (24) reported that no significant association
was observed between the intake of folate and the risk
of postpartum depression. In addition, Penninx et al.
found no association between folate or homocysteine and
depression (25).
Likewise, we also found no statistically significant
relationship between depressive symptoms and either
folate or vitamin B12 level in postmenopausal women in
our study. Depressive symptoms in the postmenopausal
women may have been affected by the presence of chronic
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diseases, cognitive impairment, and flushing that drives the
beginning or worsening of preexisting mood symptoms,
making it difficult to find an association with serum folate
and vitamin B12 levels. It was suggested that hot flushes
and poor sleep independently predicted major depressive
disorders (26). On the other hand, Leung and Kaplan
suggested that several nutrient deficiencies, including
folate deficiency, may be both a cause and a result of
mood problems (2). However, study of the effects of a
specific nutrient deficiency is usually affected by multiple
deficiencies in an undernourished subject. This may be a
cause of residual discrepancy in the studies that focus only
on folate or vitamin B12 status. This may also be the cause
of the relationship between folate and vitamin B12 levels
found in our study.
The major limitation of our study was that we were
not able to examine the risk factors for depression, such as
social factors (27), history of depression, lack of partner,
or family violence (28,29). The CES-D scale evaluates
frequency of depressive symptoms only in the previous
week; lack of evaluation and diagnosis by a psychiatrist
is also another limitation. Nonidentified medications like
methotrexate, trimethoprim, or anticonvulsants (30) and
factors interfering with folate and vitamin B12 levels (31)
may also affect the results.
The studies on this issue have conflicting results,
probably because of the multiple factors affecting
depression, nutrient intake, and multiple nutrient
deficiencies simultaneously seen in undernourished
subjects. In addition, postmenopausal symptoms may
also affect our results. In conclusion, in this study, no
correlation was detected between serum folate or vitamin
B12 levels and depressive symptoms in postmenopausal
women, and the supplementation of folic acid and vitamin
B12 for postmenopausal women does not seem to be an
effective intervention to reduce depressive symptoms.
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